Transaction Readiness for Life Sciences Companies ($2–20M ARR)

Transaction readiness means your financials would survive institutional due diligence today. For life sciences companies, that bar is higher than for a typical business, because diligence adds layers most generalist advisors miss: milestone-based revenue recognition, grant accounting, clinical-stage burn profiles, licensing and royalty structures, and regulatory timelines that directly drive valuation. A biopharma, medtech, or digital-health founder at $2–20M ARR preparing for a raise or exit needs financials that speak the language sophisticated life sciences investors and acquirers use — or the process stalls exactly where it matters most. Getting these layers right before going to market is the difference between defending your valuation and watching it get renegotiated.

What makes life sciences diligence different

• Milestone-based revenue. Payments tied to clinical, regulatory, or commercial milestones must be recognized correctly. Aggressive or inconsistent recognition is one of the first things a specialist buyer probes.
• Grant and non-dilutive funding. Grants, tax credits, and government funding carry accounting and compliance obligations that need clean documentation.
• Clinical-stage burn. Investors read your burn against your program timeline. A burn profile that doesn't map to your milestones raises immediate questions.
• Licensing and royalties. In- and out-licensing deals, royalty structures, and IP ownership must be documented and defensible — they are often the core of the valuation.
• Regulatory timelines. Where you sit relative to regulatory milestones shapes what your company is worth. Buyers price the gap between here and the next value inflection.

The readiness checklist for life sciences founders

• Three-statement model with revenue recognition mapped to milestones and contracts.
• Program-level burn analysis tied to clinical and regulatory timelines.
• Clean grant and non-dilutive funding accounting.
• Documented IP ownership, licensing terms, and royalty obligations.
• Cap table reflecting the often-complex financing history of science-led companies.
• A data room organized the way life sciences investors expect to find it.

Why this matters more at $2–20M ARR

This is the stage where science-led companies transition from grant-and-angel funding to institutional capital — Series A and beyond — or toward strategic acquisition. It is also the stage where finance infrastructure most often lags the science. Founders who close this gap early raise faster, on better terms, and avoid the value erosion that comes from scrambling to explain their financials after a term sheet is already on the table.

Frequently asked questions

What is transaction readiness for a life sciences company?
Having financials, IP documentation, and burn analysis that would survive institutional diligence today — with milestone revenue, grant accounting, and licensing structures all documented and defensible.

When should a biotech or medtech founder start preparing for a raise?
Well before you go to market — typically 6–18 months ahead. The finance and diligence work that defends your valuation takes time to do properly.

Why do generalist advisors struggle with life sciences deals?
They miss the sector-specific layers — milestone revenue recognition, grant accounting, clinical burn, and regulatory-timeline-driven valuation — that determine how specialist investors and acquirers price the company.

---

Building a science-led company at $2–20M ARR and eyeing a raise or exit? Zenith's life sciences practice does exactly this. A Transaction Readiness Audit shows you where your financials stand against how life sciences investors actually diligence — and what to fix first. Book a Transaction Readiness Audit →